EWTX News and Press, Edgewise Therapeutics Inc. From 04/15/24

– The North Star Ambulatory Assessment (NSAA) remained stable relative to declines reported in Becker natural history studies – – Significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers ...

– Presentation highlights beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy (HCM) – Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET. The presentation will be webcast live; a link for the webc...

2024-03-22 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, at 12:00 pm ET. The presentation will be webcast live; a link for the web...

– Company to host an Industry Forum to discuss its approach to protecting and preserving dystrophic muscle featuring key opinion leaders – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company wi...

2024-02-22 13:40:40 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Edgewise wins F...

2024-02-18 10:03:54 ET Summary Edgewise Therapeutics' stock has rallied massively after receiving FDA designations for its lead asset, EDG-5506, which has a potential $750 million opportunity in BMD. The company is focused on developing precision medicines for severe genetic neuro...

2024-02-13 08:37:05 ET More on Candel, Edgewise, etc. Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech added to Evercore’s Tactical Outperform list on...